![Michael Dunn](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Dunn
Präsident bei
CALCIMEDICA, INC.
Vermögen: 2 352 $ am 31.07.2026
Profil
Michael J.
Dunn is currently Director at Arisan Therapeutics, Inc., President & Chief Operating Officer at CalciMedica Subsidiary, Inc. since 2013, and President & Chief Operating Officer at CalciMedica, Inc. since 2014, with the title updated in 2020.
Former roles include Director at Aegea Biotechnologies, Inc. from 2012 to 2017; Vice President-Business Development at Sibia Neurosciences, Inc.; Chief Business Officer & Vice President at Monogram Biosciences, Inc.; SVP-Corporate Development & Business Development at Biocept, Inc. from 2011 to 2013; Chief Business Officer & Vice President at ACLARA Biosciences, Inc. from 2003 to 2004; Vice President-Business Development at Aurora Biosciences Corp.
from 1998 to 2002; and Chief Business Officer & Vice President at ActivX Biosciences, Inc. from 2002 to 2003.
Education includes undergraduate studies at The University of Chicago and an MBA from the University of San Diego.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CALCIMEDICA, INC. 0,01 % | 24.06.2025 | 2.352 ( 0,01 % ) | 2 352 $ | 31.07.2026 |
Aktive Positionen von Michael Dunn
| Unternehmen | Position | Beginn |
|---|---|---|
| CALCIMEDICA, INC. | Präsident | 01.01.2014 |
Arisan Therapeutics, Inc.
 Arisan Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapeutic for the treatment of neglected and emerging infectious diseases | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Michael Dunn
| Unternehmen | Position | Ende |
|---|---|---|
Aegea Biotechnologies, Inc.
 Aegea Biotechnologies, Inc. Medical/Nursing ServicesHealth Services Provides diagnostic testing services | Direktor/Vorstandsmitglied | 01.01.2017 |
| BIOCEPT, INC. | Corporate Officer/Principal | - |
ACLARA Biosciences, Inc.
 ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology Discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic and oncologic diseases | Corporate Officer/Principal | 01.12.2004 |
ActivX Biosciences, Inc.
 ActivX Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops drug molecule for hematology, oncology, metabolic and inflammatory diseases | Corporate Officer/Principal | 01.04.2003 |
Aurora Biosciences Corp.
 Aurora Biosciences Corp. BiotechnologyHealth Technology Designs and develops proprietary drug discovery systems, services and technologies | Corporate Officer/Principal | 01.03.2002 |
Ausbildung von Michael Dunn
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
34
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
Sibia Neurosciences, Inc.
 Sibia Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops novel, small molecule therapeutics for disorders of the nervous system | Health Technology |
Aurora Biosciences Corp.
Aurora Biosciences Corp. BiotechnologyHealth Technology Designs and develops proprietary drug discovery systems, services and technologies | Health Technology |
ACLARA Biosciences, Inc.
ACLARA Biosciences, Inc. Medical SpecialtiesHealth Technology Discovers, develops and markets innovative products to guide and improve treatment of serious viral, immunologic and oncologic diseases | Health Technology |
Monogram Biosciences, Inc.
 Monogram Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services for HIV treatment | Commercial Services |
Biocept, Inc.
 Biocept, Inc. Medical/Nursing ServicesHealth Services Develops and performs clinical laboratory tests to detection & analysis of tumor cells and cell-free DNA from cerebrospinal fluid | Health Services |
CalciMedica Subsidiary, Inc.
 CalciMedica Subsidiary, Inc. BiotechnologyHealth Technology Engages in drug development | Health Technology |
Arisan Therapeutics, Inc.
Arisan Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapeutic for the treatment of neglected and emerging infectious diseases | Health Technology |
ActivX Biosciences, Inc.
ActivX Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops drug molecule for hematology, oncology, metabolic and inflammatory diseases | Health Technology |
The University of Chicago
 The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of San Diego
 University of San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aegea Biotechnologies, Inc.
Aegea Biotechnologies, Inc. Medical/Nursing ServicesHealth Services Provides diagnostic testing services | Health Services |
CalciMedica, Inc.
 CalciMedica, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
